To determine if the pattern of GH delivery is important for the regulation of serum somatomedin-C/insulinlike growth factor I (Sm-C/IGF-I) and liver somatogenic receptors, we have measured serum Sm-C/IGF-I concentrations and free (H2O-treated homogenates) and total (MgCl2-treated homogenates) liver GH-binding sites in hypophysectomized rats treated for 7 days with rat GH (rGH), given either continuously by osmotic minipumps (50 and 250 μg/day) or intermittently (four sc injections of 12.5 μg/day). At a daily dose of 50 μg, intermittent rGH produced greater weight gain [+29.7 ± 0.8 g (mean ± SE)] than continuous GH infusion (23.3 ± 2.0 g; P < 0.01). Likewise, the serum Sm-C/IGF-I concentration rose more with intermittent (0.33 ±0.1 U/ml) than with continuous delivery (0.17 ± 0.01 U/ml; P < 0.01). The serum Sm-C/IGF-I level achieved with repeated GH injections was even greater than that after continuous delivery of a 5-fold higher GH dose (250 μg/ day; 0.27 ± 0.02 U/ml; P < 0.05). Continuous infusions of 50 and 250 μg rGH/day increased the number of liver total GH receptors by 2.5-fold over that of controls. In contrast, frequent GH injections did not affect GH binding, and the serum Sm-C/ IGF-I concentration did not correlate with liver GH-binding sites in the GH-injected rats (r = 0.189; P = NS). Induction of hepatic PRL receptors was 10-fold higher when GH was given continuously than when it was given intermittently. The close correlation observed between GH- and PRL- binding sites in all GH-treated rats (r = 0.955; P < 0.001) suggests that their regulation may be linked. These data suggest that the regulatory mechanism controlling Sm-C/IGF-I production and growth might be different from those that regulate GH receptor concentrations, with GH pulses being crucial for the maximal stimulation of Sm-C/IGF and growth, but continuous exposure to GH being required for upregulation of liver GH receptors. (Endocrinology123: 1053–1059, 1988)
We have shown that a depletion of omega3 polysaturated fatty acids (PUFAs) plays a role in the pathophysiology of depression, in part because omega3 PUFAs have anti-inflammatory effects. omega3 PUFAs are frequently employed to treat depression. Most if not all antidepressants have negative immunoregulatory effects by decreasing the production of proinflammatory cytokines, such as interferon-gamma (IFNgamma) and/or increasing that of anti-inflammatory cytokines, such as interleukin10 (IL-10).The aim of the present study was to examine the immunoregulary effects of the omega3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and the omega6 PUFA, arachidonic acid (AA), on the production of interferon-gamma (IFNgamma), interleukin-10 (IL-10) and tumor necrosis factor-alpha (TNFalpha).This study examines the ex vivo effects of EPA (4.5 microM, 9 microM, 18 microM and 45 microM), DHA (1.3 microM, 3 microM, 6 microM and 13 microM) and AA (8 microM, 16 microM, 32 microM and 80 microM) on the LPS + PHA-stimulated production of IFNgamma, IL-10 and TNFalpha, and on the IFNgamma/IL-10 production ratio.We found that EPA did not have any significant effects on the above cytokines. DHA significantly increased the IFNgamma/IL-10 production ratio, caused by a greater reduction in IL-10 than in IFNgamma. AA significantly decreased TNFalpha production.The results show that DHA induces a Th-1-like immune response and that AA has anti-inflammatory effects by decreasing the production of TNFalpha. Thus, the immune effects of omega3 PUFAs are not compatible with what is expected from antidepressive substances. The results of the present study show that treatment with fish oils, containing DHA, should be avoided in the treatment of depression. Toward this end, highly concentrated and pure EPA seems to be indicated.
There is now evidence that depression, as characterized by melancholic symptoms, anxiety, and fatigue and somatic (F&S) symptoms, is the clinical expression of peripheral cell-mediated activation, inflammation and induction of oxidative and nitrosative stress (IO&NS) pathways and of central microglial activation, decreased neurogenesis and increased apoptosis. This review gives an explanation for the multiple "co-morbidities" between depression and a large variety of a) brain disorders related to neurodegeneration, e.g. Alzheimer's, Parkinson's and Huntington's disease, multiple sclerosis and stroke; b) medical disorders, such as cardiovascular disorder, chronic fatigue syndrome, chronic obstructive pulmonary disease, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, irritable bowel syndrome, leaky gut, diabetes type 1 and 2, obesity and the metabolic syndrome, and HIV infection; and c) conditions, such as hemodialysis, interferon-α-based immunotherapy, the postnatal period and psychosocial stressors. The common denominator of all those disorders/conditions is the presence of microglial activation and/or activation of peripheral IO&NS pathways. There is evidence that shared peripheral and / or central IO&NS pathways underpin the pathophysiology of depression and the previously mentioned disorders and that activation of these IO&NS pathways contributes to shared risk. The IO&NS pathways function as a smoke sensor that detect threats in the peripheral and central parts of the body and signal these threats as melancholic, anxiety, and fatigue and somatic (F&S) symptoms. The presence of concomitant depression is strongly associated with a lower quality of life and increased morbidity and mortality in medical disorders. This may be explained since depression contributes to increased (neuro)inflammatory burden and may therefore drive the inflammatory and degenerative progression. It is concluded that the activation of peripheral and / or central IO&NS pathways may explain the co-occurrence of depression with the above disorders. This shows that depression belongs to the spectrum of inflammatory and degenerative disorders.
Developmental changes in liver somatotropic (GH) and lactogenic (PRL) binding sites were evaluated in male and female rats from birth to sexual maturity, and compared with growth velocity, plasma GH, PRL, testosterone, and estrogens. The affinity (Ka) and the concentration of these sites were determined from the analysis of equilibrium saturation curves with [125I]bovine GH and [125I]ovine PRL, incubated with liver homogenates. GH receptors rose from 6.4 fmol/mg protein at 8 days of age to 30.3 fmol/mg protein in males and 39.4 fmol/mg protein in females at 28 days. This surge occurred concomitant with the fall of plasma GH observed after birth. It preceded by about 1 week the acceleration of growth velocity and the increase of plasma GH seen at puberty. After the peak of growth velocity (42 days), GH receptors increased steadily until 120 days in females (63.8 fmol/mg protein), whereas in males they reached a concentration of 33.5 fmol/mg protein after a transient decrease to a nadir of 13.3 fmol/mg protein a day 50. From day 8 to day 35, PRL receptors in males remained at a constant level of 10.3 fmol/mg protein, whereas in females they increased progressively from 4.8 to 21.5 fmol/mg protein. Thereafter, in most pubertal males, they became undetectable, whereas plasma testosterone was rising. In contrast, PRL receptors in females increased 3-fold between day 42 (18.9 fmol/protein) and day 50 (50.2 fmol/mg protein). Between days 8 and 120, the Ko of GH and PRL receptors showed no significant changes with age and sex (GH: 0.66 x 109 M−1; PRL: 0.97 × 109m−1). In conclusion, the rise of liver GH receptors occurring before puberty in male and female rats may be of importance for the initiation of the pubertal growth spurt. The inverse relationship between plasma testosterone and liver PRL receptors in pubertal male rats suggests that physiological concentrations of testosterone may inhibit PRL receptors. In contrast, in female rats an opposite change of PRL receptors is observed during puberty. (Endocrinology113: 1325, 1983)
A review is made on the repeated dexamethasone suppression test (DST) in patients with a major depression. In those patients treated with conventional antidepressants the gradual normalization of the DST results is significantly correlated with the evolution of the clinical picture as measured with the Hamilton Depression Rating Scale. Normalization of the DST precedes symptomatic improvement and can be used as a predictor of good clinical outcome. Persistent dexamethasone non-suppression after treatment and complete clinical recovery predicts early clinical relapse. Patients with recurrent depression tend to have consistency of their response to dexamethasone over multiple depressive episodes.
Abstract Allergic contact dermatitis (ACD) is a T cell-mediated type of skin inflammation resulting from contact hypersensitivity (CHS) to antigens. There is strong comorbidity between ACD and major depression. Keratinocytes release immunomodulatory mediators including pro-inflammatory cytokines and chemokines, which modulate skin inflammation and are crucial cell type for the development of CHS. Our previous studies showed that fluoxetine and desipramine were effective in suppressing CHS in different mouse strains. However, the immune and molecular mechanisms underlying this effect remain to be explored. The aim of the current study was to determine the immune and molecular mechanisms of action of antidepressant drugs engaged in the inhibition of CHS response in the stimulated keratinocyte HaCaT cell line. The results show that LPS, TNF-α/IFN-γ, and DNFB stimulate HaCaT cells to produce large amounts of pro-inflammatory factors including IL-1β, IL-6, CCL2, and CXCL8. HaCaT stimulation was associated with increased expression of ICAM-1, a cell adhesion molecule, and decreased expression of E-cadherin. Imipramine, desipramine, and fluoxetine suppress the production of IL-1β, CCL2, as well as the expression of ICAM-1. LPS and TNF-α/IFN-γ activate p-38 kinase, but antidepressants do not regulate this pathway. LPS decreases E-cadherin protein expression and fluoxetine normalizes these effects. In summary, the antidepressant drugs examined in this study attenuate the stimulated secretion of pro-inflammatory cytokines, chemokines, and modulate adhesion molecule expression by the HaCaT cell line. Therefore, antidepressants may have some clinical efficacy in patients with ACD and patients with comorbid depression and contact allergy.
